Guillain-Barré Syndrome as a Complication of COVID-19

Adeel S Zubair1, Aarij S Zubair2, Kunal Desai1

  • 1Neurology, Yale University, New Haven, USA.

Cureus
|February 22, 2021
PubMed

Insights

Two unusual cases of Guillain-Barre syndrome (GBS) occurred eight weeks after COVID-19 infection. Prompt diagnosis and treatment with intravenous immunoglobulin therapy were effective for these neurological complications.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Immunology

Background:

  • Coronavirus disease 2019 (COVID-19) can cause various neurological complications.
  • Guillain-Barre syndrome (GBS) is a rare neurological complication associated with infections, including COVID-19.

Observation:

  • Two cases of GBS developed approximately eight weeks after initial COVID-19 infection.
  • This delayed onset is unusual for post-infectious GBS.
  • Diagnosing GBS in critically ill COVID-19 patients with prolonged hospital stays presents diagnostic challenges.

Findings:

  • Clinical suspicion, electrodiagnostic studies (nerve conduction studies and electromyography), and cerebrospinal fluid analysis are crucial for diagnosing GBS.
  • Both patients demonstrated a positive response to intravenous immunoglobulin therapy.

Implications:

  • The findings highlight the possibility of a delayed GBS onset following COVID-19.
  • Early and accurate diagnosis is essential for effective management of GBS in the context of COVID-19.
  • Intravenous immunoglobulin therapy is a viable treatment option for GBS associated with COVID-19.

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
580
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
70
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.6K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.2K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
1.7K